Apr 29, 2020
Sumitovant Biopharma Announces Publication of Myovant Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 Liberty Studies in Uterine Fibroids in Obstetrics & Gynecology
Apr 24, 2020
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
Jun 19, 2019
World Endometriosis Markets, 2014-2019 & 2019-2026: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, Patent Information, Licensing and Acquisition Deals
Nov 15, 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
Aug 22, 2018
AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 07, 2018
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
Apr 27, 2018
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 10, 2018
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Feb 13, 2018
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
Nov 01, 2017
AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Aug 10, 2017
Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017
Jun 29, 2017
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain